Stoke Therapeutics, Inc. $STOK Shares Acquired by Invesco Ltd.

Key Points

• Invesco Ltd. increased its stake in Stoke Therapeutics, Inc. by 117.0% in Q1, now owning 26,183 shares worth $174,000.
• Several analysts have rated Stoke Therapeutics as "buy," with target prices ranging from $22.00 to $35.00, reflecting positive market sentiment.
• Stoke Therapeutics reported a quarterly EPS of ($0.40), exceeding estimates, but revenue fell short at $13.82 million compared to expectations of $31.51 million.

Invesco Ltd. increased its position in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 117.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,183 shares of the company's stock after buying an additional 14,118 shares during the period. Invesco Ltd.'s holdings in Stoke Therapeutics were worth $174,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. GAMMA Investing LLC grew its holdings in Stoke Therapeutics by 1,842.0% in the first quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock valued at $36,000 after purchasing an additional 5,084 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Stoke Therapeutics by 123.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 95,505 shares of the company's stock worth $1,053,000 after buying an additional 52,813 shares during the period. ProShare Advisors LLC purchased a new stake in Stoke Therapeutics during the fourth quarter worth approximately $139,000. XTX Topco Ltd purchased a new stake in Stoke Therapeutics during the first quarter worth approximately $267,000. Finally, Millennium Management LLC grew its stake in Stoke Therapeutics by 417.9% during the fourth quarter. Millennium Management LLC now owns 76,829 shares of the company's stock worth $847,000 after buying an additional 61,994 shares during the period.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on STOK. Jefferies Financial Group began coverage on shares of Stoke Therapeutics in a research note on Friday, July 18th. They set a "buy" rating and a $30.00 price objective for the company. Needham & Company LLC reiterated a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, July 1st. Wedbush upped their target price on shares of Stoke Therapeutics from $16.00 to $22.00 and gave the company an "outperform" rating in a research note on Wednesday, August 13th. BTIG Research set a $28.00 target price on shares of Stoke Therapeutics and gave the company a "buy" rating in a research note on Monday, August 18th. Finally, Chardan Capital restated a "buy" rating and issued a $24.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating and seven have issued a Buy rating to the stock. According to MarketBeat, Stoke Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $25.57.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 6,345 shares of the stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $20.07, for a total transaction of $127,344.15. Following the sale, the general counsel directly owned 11,831 shares of the company's stock, valued at approximately $237,448.17. This represents a 34.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Barry Ticho sold 5,501 shares of the stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $19.87, for a total transaction of $109,304.87. Following the sale, the insider directly owned 18,469 shares in the company, valued at $366,979.03. This trade represents a 22.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 107,719 shares of company stock valued at $2,063,359 over the last ninety days. Corporate insiders own 9.50% of the company's stock.

Stoke Therapeutics Price Performance

STOK traded down $0.42 during trading on Friday, hitting $23.46. The company had a trading volume of 1,030,859 shares, compared to its average volume of 957,451. The company has a market cap of $1.29 billion, a PE ratio of 27.60 and a beta of 1.14. The business has a 50-day moving average of $16.05 and a 200-day moving average of $11.54. Stoke Therapeutics, Inc. has a 1-year low of $5.35 and a 1-year high of $24.60.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.17. The firm had revenue of $13.82 million for the quarter, compared to analysts' expectations of $31.51 million. Stoke Therapeutics had a net margin of 26.25% and a return on equity of 18.32%. Research analysts forecast that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current year.

Stoke Therapeutics Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.